CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological...
Multiple Myeloma in RelapseMultiple Myeloma7 moreA Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological...
Acute Lymphoblastic LeukemiaNon-hodgkin LymphomaA study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaA Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
T-cell Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin LymphomaThis is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute...
Acute Lymphoblastic LeukemiaPediatric2 moreWith this research study has following goals To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. To learn more about side effects of palbociclib in combination with chemotherapy; To learn more about the biological effects of palbociclib on the cells in your body
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune...
Cytokine Release SyndromeICANS4 moreThis study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia....
Lymphoblastic LeukemiaAcute7 moreThe objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell...
LeukemiaMyeloid12 moreThis is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned for allogeneic stem cell transplantation (alloSCT). The primary study objective is to determine the safety and maximum tolerated dose of venetoclax when used in combination with fludarabine and cyclophosphamide conditioning. Secondary objectives were to evaluate the transplant outcomes and donor/recipient engraftment of this regimen.
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults...
LymphomaNon-Hodgkin9 moreThis is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in...
T-cell Acute Lymphoblastic LeukemiaLymphoblastic LymphomaThe main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).